TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LIQREV

SILDENAFIL CITRATE
Approved 2023-04-28
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Discontinued
First Approved
2023-04-28
Routes
ORAL
Dosage Forms
SUSPENSION

Companies

CMP DEV LLC
Active Ingredient: SILDENAFIL CITRATE

LIQREV Approval History

Loading approval history...

What LIQREV Treats

1 FDA approvals

Originally approved for its first indication in 2023 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LIQREV FDA Label Details

Pro

LIQREV Patents & Exclusivity

Latest Patent: Dec 2038

Patents (5 active)

US11337979 Expires Dec 24, 2038
US11464778 Expires Dec 24, 2038
US12186321 Expires Dec 24, 2038
US11759468 Expires Dec 24, 2038
US12005062 Expires Dec 24, 2038
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA214952 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.